Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 06, 2020 16:05 ET | Source: Pfenex, Inc.

Pfenex Reports Second Quarter 2020 Results and Provides Business Update

Commercialization and launch of first royalty bearing products position company for next phase of growthMultiple U.S. health plans add Teriparatide Injection to their formulary upon its June 2020...
July 20, 2020 08:30 ET | Source: Pfenex, Inc.

Pfenex to Announce Second Quarter Financial Results on August 6

SAN DIEGO, July 20, 2020 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) announced today that it will report its financial results for the second quarter ended June 30, 2020, after the market...
June 26, 2020 14:05 ET | Source: Pfenex, Inc.

Pfenex Announces Positive European CHMP Opinion for PF708 (EU Brand Name: Livogiva™) and New Partnership in Latin America, and Provides CRM197 Business Update

Positive Opinion from Committee for Medicinal Products for Human Use (CHMP) for Livogiva marks important first step toward marketing authorizationPfenex’s commercial partner Adalvo entered into...
June 12, 2020 08:00 ET | Source: Pfenex, Inc.

Pfenex Announces U.S. Commercial Launch of Teriparatide Injection

Pfenex’s commercialization partner Alvogen will lead launch and commercialization efforts in the United StatesThe first FDA-approved teriparatide with Forteo® 1-3 as the reference drug SAN DIEGO,...
June 05, 2020 09:00 ET | Source: Pfenex, Inc.

Pfenex to Participate in the William Blair Growth Stock Conference

SAN DIEGO, June 05, 2020 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) announced today that Eef Schimmelpennink, President and Chief Executive Officer, will participate in a fire side chat...
May 07, 2020 16:05 ET | Source: Pfenex, Inc.

Pfenex Reports First Quarter 2020 Results and Provides Business Update

SAN DIEGO, May 07, 2020 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) is a development and licensing biotechnology company focused on leveraging its proprietary protein production platform,...
April 24, 2020 16:05 ET | Source: Pfenex, Inc.

Pfenex to Announce First Quarter 2020 Financial Results on May 7

SAN DIEGO, April 24, 2020 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) announced today that it will report its financial results for the first quarter ended March 31, 2020, after the market...
April 14, 2020 17:04 ET | Source: Pfenex, Inc.

Pfenex Announces FDA Requests Additional Comparative Use Human Factors Data in Experienced Users in order to Complete PF708 Therapeutic Equivalence Determination

SAN DIEGO, April 14, 2020 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) announced today that the U.S. Food and Drug Administration (FDA), informed Alvogen Malta Operations Ltd., the...
March 11, 2020 16:05 ET | Source: Pfenex, Inc.

Pfenex Reports Fourth Quarter and Full Year 2019 Results and Provides Business Update

Alvogen is preparing for commercial launch of PF708 upon receiving FDA decision on therapeutic equivalence to Forteo® Jazz initiated a pivotal Phase 2/3 Study for FDA fast track designated PF743...
February 26, 2020 17:03 ET | Source: Pfenex, Inc.

Pfenex to Announce Fourth Quarter and Year-End 2019 Financial Results on March 11

SAN DIEGO, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) announced today that it will report its financial results for the fourth quarter and year ended December 31, 2019,...